NCT02327403View on ClinicalTrials.gov

Belatacept Conversion in Proteinuric Kidney Transplant Recipients

PHASE2CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 30, 2020

Study Completion Date

October 1, 2020

Conditions

Proteinuria

Interventions

DRUG

Belatacept

Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Brigham and Women's Hospital

OTHER